Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 3
2008 3
2009 2
2010 3
2011 1
2012 1
2013 3
2014 2
2015 2
2016 3
2017 1
2018 5
2020 1
2021 4
2022 3
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Results by year

Filters applied: . Clear all
Page 1
Rapid transient and longer-lasting innate cytokine changes associated with adaptive immunity after repeated SARS-CoV-2 BNT162b2 mRNA vaccinations.
Rosati M, Terpos E, Homan P, Bergamaschi C, Karaliota S, Ntanasis-Stathopoulos I, Devasundaram S, Bear J, Burns R, Bagratuni T, Trougakos IP, Dimopoulos MA, Pavlakis GN, Felber BK. Rosati M, et al. Among authors: bergamaschi c. Front Immunol. 2023 Nov 27;14:1292568. doi: 10.3389/fimmu.2023.1292568. eCollection 2023. Front Immunol. 2023. PMID: 38090597 Free PMC article.
Comparative immunogenicity of an mRNA/LNP and a DNA vaccine targeting HIV gag conserved elements in macaques.
Valentin A, Bergamaschi C, Rosati M, Angel M, Burns R, Agarwal M, Gergen J, Petsch B, Oostvogels L, Loeliger E, Chew KW, Deeks SG, Mullins JI, Pavlakis GN, Felber BK. Valentin A, et al. Among authors: bergamaschi c. Front Immunol. 2022 Jul 22;13:945706. doi: 10.3389/fimmu.2022.945706. eCollection 2022. Front Immunol. 2022. PMID: 35935984 Free PMC article.
Reduced Antibodies and Innate Cytokine Changes in SARS-CoV-2 BNT162b2 mRNA Vaccinated Transplant Patients With Hematological Malignancies.
Bergamaschi C, Pagoni M, Rosati M, Angel M, Tzannou I, Vlachou M, Darmani I, Ullah A, Bear J, Devasundaram S, Burns R, Baltadakis I, Gigantes S, Dimopoulos MA, Pavlakis GN, Terpos E, Felber BK. Bergamaschi C, et al. Front Immunol. 2022 May 25;13:899972. doi: 10.3389/fimmu.2022.899972. eCollection 2022. Front Immunol. 2022. PMID: 35693807 Free PMC article.
Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors.
Conlon K, Watson DC, Waldmann TA, Valentin A, Bergamaschi C, Felber BK, Peer CJ, Figg WD, Potter EL, Roederer M, McNeel DG, Thompson JA, Gupta S, Leidner R, Wang-Gillam A, Parikh NS, Long D, Kurtulus S, Ho Lee L, Chowdhury NR, Bender F, Pavlakis GN. Conlon K, et al. Among authors: bergamaschi c. J Immunother Cancer. 2021 Nov;9(11):e003388. doi: 10.1136/jitc-2021-003388. J Immunother Cancer. 2021. PMID: 34799399 Free PMC article. Clinical Trial.
Systemic IL-15, IFN-γ, and IP-10/CXCL10 signature associated with effective immune response to SARS-CoV-2 in BNT162b2 mRNA vaccine recipients.
Bergamaschi C, Terpos E, Rosati M, Angel M, Bear J, Stellas D, Karaliota S, Apostolakou F, Bagratuni T, Patseas D, Gumeni S, Trougakos IP, Dimopoulos MA, Felber BK, Pavlakis GN. Bergamaschi C, et al. Cell Rep. 2021 Aug 10;36(6):109504. doi: 10.1016/j.celrep.2021.109504. Epub 2021 Jul 23. Cell Rep. 2021. PMID: 34352226 Free PMC article.
Heterodimeric IL-15 in Cancer Immunotherapy.
Bergamaschi C, Stravokefalou V, Stellas D, Karaliota S, Felber BK, Pavlakis GN. Bergamaschi C, et al. Cancers (Basel). 2021 Feb 17;13(4):837. doi: 10.3390/cancers13040837. Cancers (Basel). 2021. PMID: 33671252 Free PMC article. Review.
36 results